Stocksigma LogoStocksigma Logo

Influx Healthtech Delivers Robust H1 FY27 Growth with Expanding CDMO Capacities

Influx Healthtech reported H1 FY27 revenue of ₹85.4 cr, up 27.9% YoY, driven primarily by nutraceuticals (88% mix)

Influx Healthtech Delivers Robust H1 FY27 Growth with Expanding CDMO Capacities

Influx Healthtech Ltd · Investor Presentation · 05 Nov 2026, 6:01 pm

Influx Healthtech Delivers Robust H1 FY27 Growth with Expanding CDMO Capacities Influx Healthtech reported H1 FY27 revenue of ₹85.4 cr, up 27.9% YoY, driven primarily by nutraceuticals (88% mix). EBITDA rose 25.1% YoY to ₹18.3 cr with a 21.5% margin, while PAT expanded 20.0% YoY to ₹12.0 cr (14.1% margin). Annualized RoE and RoCE reached 21.4% and 28.1%, respectively, backed by a zero-debt balance sheet. The company targets 25% growth in FY27, supported by ongoing commercialization at its new 75,000 sq. ft. Palghar facility, automated line additions, and an expected 2.5x capacity expansion post-IPO proceeds utilization.

Original exchange filing (PDF)

More announcements from Influx Healthtech Ltd

All Influx Healthtech Ltd announcements